The Alzheimer's Drug Discovery Foundation (ADDF) has funded Madera Biosciences with a sum of $298,500 to advance the development of the company’s small molecule drugs.
The drugs are intended to clear the accumulated beta-amyloid from the brain resulting in a halt or reverse the series of Alzheimer's disease.
The company has recognized a progression of small molecule compounds that improve the expression of apolipoprotein E (apoE), a lipid-binding protein that circulates in the blood and the brain.
The apoE has been exposed to mediate beta-amyloid approval from the brain and stop its accumulation into the plaques that are typical cause for Alzheimer's disease.
Increased release of apoE from brain cells has showed the minimized beta-amyloid plaques.
Madera CEO Rick Jack said that the ADDF's support is critical to achieve the goal of providing Alzheimer's patients a therapy that changes the course of the disease.
"These funds will allow us to gain a better in vivo understanding of how our compounds affect the pathologies caused by beta-amyloid deposition," Jack added.
The ADDF's funding will permit Madera to move forward through these compounds for proof-of-concept testing in animal models of Alzheimer's disease.
